Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Current Assets (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Current Assets for 4 consecutive years, with $589.0 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 21.42% to $589.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $589.0 million through Dec 2025, up 21.42% year-over-year, with the annual reading at $589.0 million for FY2025, 21.42% up from the prior year.
  • Current Assets hit $589.0 million in Q4 2025 for Axsome Therapeutics, up from $565.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $589.0 million in Q4 2025 to a low of $86.8 million in Q1 2022.
  • Historically, Current Assets has averaged $412.6 million across 4 years, with a median of $482.1 million in 2024.
  • Biggest five-year swings in Current Assets: skyrocketed 399.81% in 2023 and later dropped 10.9% in 2024.
  • Year by year, Current Assets stood at $245.6 million in 2022, then surged by 105.28% to $504.3 million in 2023, then dropped by 3.81% to $485.1 million in 2024, then grew by 21.42% to $589.0 million in 2025.
  • Business Quant data shows Current Assets for AXSM at $589.0 million in Q4 2025, $565.3 million in Q3 2025, and $536.6 million in Q2 2025.